Aimovig (erenumab-aooe) works to help prevent chronic migraine headaches by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule that is involved in migraine attacks and rises during an attack. The calcitonin gene-related peptide (CGRP) receptor antagonists are a new class of drugs for migraine. Aimovig, from Amgen, is also the first fully human monoclonal antibody for migraine prevention. This treatment for adults is given once-a-month by subcutaneous (under the skin) self-injections with an auto-injector type pen or a single-dose prefilled syringe.
Subscribe to receive email notifications whenever new articles are published.
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex (updated Dec 6th, 2018), Cerner Multum™ (updated Dec 7th, 2018), Wolters Kluwer™ (updated Dec 5th, 2018) and others. To view content sources and attributions, please refer to our editorial policy.